-
Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone.
Ruglass LM, Scodes J, Pavlicova M, Campbell ANC, Fitzpatrick S, Barbosa-Leiker C, Burlew AK, Greenfield SF, Rotrosen J, Nunes EV. Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone. Drug and Alcohol Dependence 2019;205:107649.
-
Pharmacists’ attitudes toward dispensing naloxone and medications for opioid use disorder: A scoping review of the literature.
Muzyk A, Smothers ZPW, Collins K, MacEachern M, Wu L. Pharmacists' attitudes toward dispensing naloxone and medications for opioid use disorder: A scoping review of the literature. Substance Abuse 2019;40(4):476-483.
-
Electronic self-administered screening for substance use in adult primary care patients: Feasibility and acceptability of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (myTAPS) screening tool.
Adam A, Schwartz RP, Wu L, Subramaniam G, Laska E, Sharma G, Mili S, McNeely J. Electronic self-administered screening for substance use in adult primary care patients: Feasibility and acceptability of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (myTAPS) screening tool. Addiction Science & Clinical Practice 2019;14:39.
-
Interpretation and integration of the federal substance use privacy protection rule in integrated health systems: A qualitative analysis.
Campbell ANC, McCarty D, Rieckmann TR, McNeely J, Rotrosen J, Wu L, Bart G. Interpretation and integration of the federal substance use privacy protection rule in integrated health systems: A qualitative analysis. Journal of Substance Abuse Treatment 2019;97:41-46.
-
Acute and long-term cannabis use among stimulant users: Results from CTN-0037 STimulant Reduction Intervention using Dosed Exercise (STRIDE) randomized control trial.
Vidot DC, Rethorst CD, Carmody TJ, Stoutenberg M, Walker NR, Greer TL, Trivedi MH. Acute and long-term cannabis use among stimulant users: Results from CTN-0037 STimulant Reduction Intervention using Dosed Exercise (STRIDE) randomized control trial. Drug and Alcohol Dependence 2019;200:139-144
-
Towards detecting cocaine use using smartwatches in the NIDA Clinical Trials Network: Design, rationale, and methodology.
Holtyn AF, et al. Towards detecting cocaine use using smartwatches in the NIDA Clinical Trials Network: Design, rationale, and methodology. Contemporary Clinical Trials Communications 2019;15:100392
-
Clinical workflow and substance use screening, brief intervention, and referral to treatment data in the electronic health records: A National Drug Abuse Treatment Clinical Trials Network study.
Wu L, Payne EH, Roseman K, Kingsbury C, Case A, Nelson C, Lindblad R. Clinical workflow and substance use screening, brief intervention, and referral to treatment data in the electronic health records: A National Drug Abuse Treatment Clinical Trials Network study. eGEMS 2019;7(1):1-15
-
Screening for substance use in rural primary care: A qualitative study of providers and patients.
Saunders EC, Moore SK, Gardner T, Farkas S, Marsch LA, McLeman B, Meier A, Nesin N, Rotrosen J, Walsh O, McNeely J. Screening for substance use in rural primary care: A qualitative study of providers and patients. Journal of General Internal Medicine 2019;34(12):2824-2832.
-
Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of patients with opioid use disorder.
Evans E, Yoo C, Huang D, Saxon AJ, Hser YI. Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of patients with opioid use disorder. Journal of Substance Abuse Treatment 2019;106:19-28.
-
Differential posttreatment outcomes of methylphenidate for smoking cessation for individuals With ADHD.
Luo SX, Covey LS, Hu M, Winhusen TJ, Nunes EV. Differential posttreatment outcomes of methylphenidate for smoking cessation for individuals With ADHD. American Journal on Addictions 2019;28(6):497-502.